Antibody Interest Group
The NIH Antibody Interest Group (ABIG) aims to promote information exchange and interaction among NIH scientists who work on various aspects of antibody engineering and therapy. The success of antibody therapy requires a deep understanding of biological systems in relation to molecular and cell biology, immunology, biochemistry, and microbiology as well as diseases such as cancer, autoimmunity, and infectious diseases. Interest in antibody therapy crosses traditional biomedical disciplinary boundaries. ABIG provides an open forum for multidisciplinary discussion among colleagues who otherwise may have limited contact. The principal ABIG activities are monthly meetings on current topics. The monthly ABIG meetings are open to everyone interested. These meetings are devoted to research seminars on numerous aspects of antibody engineering and therapy that will be presented by both NIH scientists and outside speakers.
To join the Antibody Interest Group mailing list, please visit the Antibody Interest Group Listserv home page, then click the “Subscribe or Unsubscribe” link in the right sidebar.
- Mitchell Ho, Ph.D., NCI/CCR
- Dimiter Dimitrov, Ph.D., NCI/CCR
- Raffit Hassan, M.D., NCI/CCR
Scientific Focus Areas
Biomedical Engineering and Biophysics
View SIGs in Biomedical Engineering and Biophysics
Learn more about Biomedical Engineering and Biophysics in the IRP
View SIGs in Clinical Research
Molecular Biology and Biochemistry
View SIGs in Molecular Biology and Biochemistry
Learn more about Molecular Biology and Biochemistry in the IRP
This page was last updated on Thursday, August 12, 2021